The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
Pina Ziranu(University of Cagliari), Mario Scartozzi(University of Cagliari), Vittorina Zagonel(Istituto Oncologico Veneto), Maria Giuseppina Sarobba, Stefano Cascinu(Vita-Salute San Raffaele University), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Sara Lonardi(Istituto Oncologico Veneto), Giordano Beretta(Humanitas Gavazzeni), Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Sandro Barni, Bruno Daniele(Azienda Ospedaliera G.Rummo), Lorenza Rimassa(Humanitas University), Laura Demurtas(University of Cagliari), Nicoletta Pella(University of Udine), Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Roberto Labianca(Ospedale Papa Giovanni XXIII), Giovanni Luca Frassineti, Daris Ferrari, Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Marco Puzzoni(University of Cagliari), Armando Santoro(IRCCS Humanitas Research Hospital), Giuseppe Palmieri(University of Sassari)
Cited by 4
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k